Secure the Future - Stop TB Partnership

Partnership objective

Strengthen the involvement of non-governmental organizations in community-based TB and TB/HIV care.

Dr. Margaret Chan, director-general, WHO and Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb Dr. Margaret Chan, director-general, WHO and Lamberto Andreotti, chief executive officer, Bristol-Myers Squibb Copyright Business Wire

What are the health needs and challenges?

Tuberculosis (TB) co-infection among HIV/AIDS patients is a neglected problem. According to the World Health Organization (WHO), 80% of the world’s HIV/TB burden is in Africa, where South Africa is ranked second to Swaziland among areas most affected. South Africa, Tanzania, Kenya, Ethiopia and Democratic Republic of the Congo collectively represented more than 13% of global TB and more than one-third of the global TB/HIV co-infection burden in 2009.

Description of partnership activities and how they address needs and challenges

In October 2011, BMS Foundation’s Secure the Future initiative and the World Health Organization’s (WHO) Stop TB Department announced a partnership to leverage Secure the Future’s Technical Assistance Program faculty in sub-Saharan Africa to increase the scaling up of successful models of community TB and TB/HIV care. 

The partners work with national TB and HIV/AIDS control programs in South Africa, Tanzania, Kenya, Ethiopia and the Democratic Republic of the Congo to promote development of policies and programs that will enable greater involvement of NGOs and civil society organizations in TB community care and the creation of a more cost-effective and sustainable TB response.

The partnership seeks to enhance earlier detection of people with TB to ensure they are treated successfully and have better access to TB services, especially in HIV prevalent settings. TB services will be strengthened and improved by embracing the advantages that NGOs can bring, such as access to remote areas and a better understanding of local needs, especially among vulnerable groups.

The partners develop and disseminate a simplified global policy to guide national TB and HIV/AIDS programs in their efforts to improve community-based TB and TB/HIV prevention, treatment and care. They will also develop monitoring and evaluation guidelines for community-based TB and TB/HIV care, including standardized indicators and reporting formats, and will develop and disseminate a training manual on community-based TB and TB/HIV care.

Lessons learned                         

WHO cites several factors complicating past efforts to effectively address the problem of co-infection of TB and HIV/AIDS in sub-Saharan Africa. These include weak collaboration between civil society organizations and national TB programs for planning, coordination, supervision and sharing of data, lack of focus and poor quality of activities.

Enhancing the linkages between national treatment plans and NGOs – including the establishment of an effective monitoring and evaluation system – will be crucial to address such problems and help the scaling up of effective community-based TB and TB/HIV care.

Building capacity to function in difficult to reach and remote areas offers a unique opportunity for increased early case detection and treatment and to transform the TB prevention, care and control efforts beyond health facilities and in areas and settings where the National TB control programs cannot reach out in a systematic way (e.g., conflict zones, prisons).

Partnership information

Company(ies) Bristol-Myers Squibb

Partner(s) Stop TB Partnership, World Health Organization (WHO)

Type of Partner(s) IGOs, Multilaterals

Therapeutic Focus Infectious Diseases

Disease(s) Tuberculosis

Program Type(s) Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) Children, Marginalised / Indigenous People, Men, Mothers, Patients in needs of treatment, People with low income, Women

Region(s) Sub-Saharan Africa

Number of Countries 5

Country(ies) Democratic Republic of the Congo, Ethiopia, Kenya, South Africa, Tanzania

Start Date 2011

More information Press Release

Anticipated completion date 2016

« Our work in TB and HIV co-infection has demonstrated the positive impact that community support can have on tracking, follow-up of results and treatment for infected individuals. »

Lamberto Andreotti, CEO, Bristol-Myers Squibb